Enanta Pharmaceuticals (ENTA) Receives $56.33 Consensus PT from Brokerages

Enanta Pharmaceuticals (NASDAQ:ENTA) has been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $56.33.

ENTA has been the topic of a number of research reports. ValuEngine raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a report on Monday, February 12th. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 10th. Royal Bank of Canada reissued a “hold” rating and set a $80.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday, April 4th. Finally, JPMorgan Chase lowered Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, February 8th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ENTA traded up $3.50 during trading hours on Thursday, reaching $89.45. 59,290 shares of the stock traded hands, compared to its average volume of 209,258. The stock has a market cap of $1,647.43, a price-to-earnings ratio of 95.70 and a beta of 1.07. Enanta Pharmaceuticals has a 52-week low of $29.46 and a 52-week high of $95.91.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.73. The company had revenue of $38.11 million for the quarter, compared to analysts’ expectations of $27.26 million. Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. sell-side analysts anticipate that Enanta Pharmaceuticals will post 0.86 earnings per share for the current fiscal year.

In related news, Treasurer Paul J. Mellett sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $86.48, for a total transaction of $778,320.00. Following the transaction, the treasurer now directly owns 96,458 shares in the company, valued at approximately $8,341,687.84. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 10.56% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its position in Enanta Pharmaceuticals by 4.3% during the 4th quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock worth $137,521,000 after acquiring an additional 97,054 shares during the last quarter. First Manhattan Co. grew its position in Enanta Pharmaceuticals by 14.5% during the 4th quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock worth $63,620,000 after acquiring an additional 137,100 shares during the last quarter. Farallon Capital Management LLC grew its position in Enanta Pharmaceuticals by 124.3% during the 4th quarter. Farallon Capital Management LLC now owns 925,000 shares of the biotechnology company’s stock worth $54,279,000 after acquiring an additional 512,667 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Enanta Pharmaceuticals by 13.3% in the 4th quarter. Renaissance Technologies LLC now owns 771,600 shares of the biotechnology company’s stock worth $45,277,000 after buying an additional 90,500 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Enanta Pharmaceuticals by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after buying an additional 7,617 shares during the last quarter. Institutional investors and hedge funds own 73.26% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by registrarjournal.com and is the property of of registrarjournal.com. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://registrarjournal.com/2018/04/17/enanta-pharmaceuticals-enta-receives-56-33-consensus-pt-from-brokerages.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply